These findings provide novel insights into the complex interplay between antimicrobial proteins, the microbiota, and intestinal health, highlighting the potential of RNASE4 as a diagnostic biomarker and therapeutic target for IBD. Here, RNASE4 is linked to inflammatory bowel disease.